Investigating how HIF2 affects pancreatic cancer growth
Official title: The Role of HIF2 in Pancreatic Ductal Adenocarcinoma
Funded at University of Tx Md Anderson Can Ctr · NIH-11030249 · Data updated 2026-11-12
This study is looking at how a specific protein called HIF2 affects the growth of pancreatic cancer and the surrounding support cells, with the hope that understanding this could help create better treatments for patients battling this tough cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $515,400 |
| NIH project number | 5R01CA269565-03 |
| Project ID | NIH-11030249 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma.
✕Less likely to help
Patients with other types of cancer or those not diagnosed with pancreatic ductal adenocarcinoma may not benefit from this research.
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a type of cancer that is difficult to treat due to its unique environment that limits blood flow and nutrient delivery. The study examines the role of hypoxia-inducible factor 2 (HIF2) in cancer-associated fibroblasts (CAFs), which are key components of the tumor's stroma. By using a specialized mouse model, researchers aim to understand how HIF2 influences tumor growth and the immune response within the tumor. The findings could lead to new therapeutic strategies that target the stroma to improve treatment outcomes for patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer by targeting the tumor environment.
How similar studies have gone: Other research has shown promising results in targeting the tumor microenvironment in various cancers, suggesting potential for success in this approach.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Koong, Albert — University of Tx Md Anderson Can Ctr
- Study coordinator: Koong, Albert
Related research
Other NIH-funded projects on the same topics.
-
Fibrin-rich tumor stroma as a new driver of immune response in pancreatic cancer
This grant explores how fibrin-involved tumor surroundings in pancreatic cancer might affect immune therapy, with the goal of making treatments work better for patients.
-
TREM2+ macrophages and liver metastases in pancreatic cancer
Researchers are studying immune cells in liver metastases from pancreatic cancer to understand how they influence the cancer’s spread and more effective treatments.
-
Protein S could slow pancreatic cancer and blood clots
A potential treatment study looks at restoring a natural blood protein, Protein S, to help people with pancreatic cancer by slowing tumor growth and reducing dangerous clots.
-
In vivo B7-H3 CAR-T cells for pancreatic cancer therapy
A patient-friendly look at a new approach that aims to produce CAR-T cells directly inside the body to target pancreatic cancer.
-
Metabolic changes in pancreatic cancer when treated with crisantaspase
Aims to understand how pancreatic cancer cells adapt their metabolism when treated with crisantaspase to inform better treatment strategies for patients.
-
New combination therapy for pancreatic cancer in animals
A new therapy designed to weaken the tumor’s protective surroundings and boost treatment effects in pancreatic cancer models.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.